SEG Opportunity Fund exits Silo Pharma stake

SEG Opportunity Fund, LLC has filed an amended Schedule 13G for Silo Pharma, Inc. reporting that it no longer beneficially owns any shares of the company’s common stock.

Rhea-AI Filing Summary

SEG Opportunity Fund, LLC has filed an amended Schedule 13G for Silo Pharma, Inc. reporting that it no longer beneficially owns any shares of the company’s common stock. The filing shows 0 shares with 0.0% of the class, with no sole or shared voting or dispositive power.

The report confirms that the securities previously held were not acquired or held for the purpose of changing or influencing control of Silo Pharma, and that SEG Opportunity Fund’s ownership has fallen to 5% or less of the outstanding common stock.

Insights

Equity ownership and disclosure analyst

SEG Opportunity Fund now reports 0% ownership in Silo Pharma.

The amended Schedule 13G shows SEG Opportunity Fund, LLC reporting beneficial ownership of 0 shares and 0.0% of Silo Pharma common stock. It also indicates no sole or shared voting or dispositive power over any shares.

The certification states the securities were not held to change or influence control of the company. The key implication is that this holder is no longer a 5% or greater beneficial owner, which reduces its formal reporting obligations under beneficial ownership rules.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SEG Opportunity Fund Schedule 13G/A say about Silo Pharma (SILO) ownership?

SEG Opportunity Fund, LLC now reports beneficial ownership of 0 shares of Silo Pharma common stock, representing 0.0% of the class. The filing confirms no sole or shared voting or dispositive power over any Silo Pharma shares.

Who is the reporting person in this Silo Pharma (SILO) Schedule 13G/A amendment?

The reporting person is SEG Opportunity Fund, LLC, a New York limited liability company. Its principal business address is listed as 135 Sycamore Drive, Roslyn, NY 11576, and it previously reported holdings in Silo Pharma’s common stock.

What percentage of Silo Pharma (SILO) does SEG Opportunity Fund currently own?

SEG Opportunity Fund reports ownership of 0.0% of Silo Pharma’s common stock. The Schedule 13G/A shows an aggregate beneficial ownership amount of 0 shares, indicating that it is no longer a 5% or greater beneficial owner.

Does SEG Opportunity Fund have voting or dispositive power over Silo Pharma (SILO) shares?

The filing states SEG Opportunity Fund has 0.00 shares with sole or shared voting power and 0.00 shares with sole or shared dispositive power. This means it does not control how any Silo Pharma shares are voted or disposed of.

What is the event date for SEG Opportunity Fund’s amended 13G on Silo Pharma (SILO)?

The Schedule 13G/A lists the Date of Event requiring the filing as February 13, 2026. This date reflects when the ownership status that triggered this amended beneficial ownership report occurred for Silo Pharma common stock.

Does SEG Opportunity Fund seek to influence control of Silo Pharma (SILO)?

The certification states the securities referenced were not acquired and are not held to change or influence control of Silo Pharma. It further notes they are not held in connection with any transaction having that purpose or effect, subject to limited nomination-related activities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 12:26 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Silo Pharma, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

82711P201

(CUSIP Number)

02/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 82711P201

1

Names of Reporting Persons

SEG Opportunity Fund, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silo Pharma, Inc.
(b)	Address of issuer's principal executive offices: 677 N. Washington Boulevard Sarasota, FL 34236
Item 2.
(a)	Name of person filing: This statement is filed by SEG Opportunity Fund, LLC, a New York limited liability company.
(b)	Address or principal business office or, if none, residence: The address of SEG Opportunity Fund, LLC is 135 Sycamore Drive Roslyn, NY 11576.
(c)	Citizenship: SEG Opportunity Fund, LLC is a New York limited liability company.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 82711P201
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover pages(s) hereto.
(b)	Percent of class: See Item 11 on the cover page(s) hereto.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SEG Opportunity Fund, LLC

Signature:	/s/ Joseph Reda
Name/Title:	Joseph Reda / Manager
Date:	02/13/2026